EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A



A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A



Blood 83(9): 2428-2435



In July 1990, the Recombinate Study Group initiated a prospective, open-labeled investigation of recombinant factor VIII (r-FVIII) to assess its safety and efficacy and to characterize the natural history of inhibitor development in previously untreated patients (PUPs) with hemophilia A. All study subjects have severe FVIII deficiency (baseline FVIII level ltoreq 2% of normal) and no history of blood product exposure before study entry.

(PDF emailed within 1 workday: $29.90)

Accession: 008048749

Download citation: RISBibTeXText



Related references

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 83(9): 2428-2435, 1994

Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thrombosis and Haemostasis 83(6): 844-848, 2000

A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thrombosis and Haemostasis 77(4): 660-667, 1997

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine 328(7): 453-459, 1993

A multicenter study of recombinant factor VIII (Recombinate(TM) ) in previously treated patients with hemophilia A. Haemophilia 3(3): 232-232, 1997

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: Safety, efficacy and development of inhibitors. New England Journal of Medicine 328(7): 453-459, 1993

Transient inhibitors in recipients of recombinant factor VIII A report from the recombinate-TM study of previously untreated patients. Blood 86(10 SUPPL 1): 193A, 1995

The use of recombinant factor VIII products in previously treated patients with hemophilia A: pharmacokinetics, efficacy, safety, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 241-246, 2002

First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Seminars in Thrombosis and Hemostasis 28(3): 273-276, 2002

Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group. Transfusion Medicine Reviews 6(4): 252-255, 1992

Recombinant FVIII treatment of previously untreated patients with hemophilia A Update of safety, efficacy and inhibitor development after 5 study years. Pediatric Research 37(4 PART 2): 161A, 1994

Safety and efficacy of ReFacto, the B domain-deleted recombinant factor VIII , in home therapy of previously treated patients with severe hemophilia A An Italian multicenter trial. Blood 96(11 Part 1): 262a, November 16, 2000

Safety, efficacy and inhibitor development in previously untreated patients treated exclusively with recombinant B-domain deleted F VIII 25 study years. Blood 90(10 SUPPL 1 PART 1): 599A, Nov 15, 1997

A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thrombosis & Haemostasis 78(5): 1352-1356, 1997

Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group. International Journal of Hematology 62(1): 35-43, 1995